Where should life sciences companies file patents? Explore the commercial and legal factors that shape filing strategies, from market size and enforcement to patentability and exclusivity.
The High Court’s decision in Parabolica v Tesla confirms that the original EUTM filing date is the relevant date for assessing absolute grounds under the Brexit transitional regime.
Discover the key patent challenges facing agrochemical innovators in Europe, from inventive step and synergy data to SPCs, UPC strategy, formulations and freedom-to-operate considerations.
In Omnia v Sidel, the UPC Court of Appeal confirmed proceedings can be brought before a European patent is granted, reinforcing the need to file UPC opt-outs soon after publication.
As consumers increasingly choose skincare based on ingredients like retinol and niacinamide, companies may need to rethink patent strategies, placing greater emphasis on manufacturing innovation.
The enhanced UK-Switzerland FTA provides greater certainty on IP rights and exclusivity, supports cross-border collaboration and investment and streamlines talent mobility for pharma and biotech innovators.
A patent does not automatically grant the right to commercialise. Discover how competitor patent watching helps deep-tech businesses identify risks, monitor rivals and prepare for future freedom-to-operate reviews.
The UAE now permits trade mark filings for alcoholic beverages in Class 33 and beer in Class 32, aligning more closely with NICE Classification standards and offering stronger protection for brands.
A comparison of UPC and EPO jurisdiction, examining early UPC decisions on competence, long-arm jurisdiction, infringement, validity challenges and cross-border patent disputes.
As circular beauty gains momentum, cosmetics brands are investing in refill systems, sustainable materials and new product formats.
